About the Report
Hyaluronic acid products have extensive application profile for various chronic complications. It constitutes synovial fluid, which has made it an excellent inclusion in the therapy for osteoarthritis pain management. The moisture-retaining capacity of hyaluronic acid makes it’s a suitable candidate for dry eye disease treatment. The demand for hyaluronic acid products demand is rising with the increasing usage in the dermatology and aesthetics for the wrinkle augmentation and volume restorative therapies.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for hyaluronic acid products. The report tracks the global sales of hyaluronic acid products in 20+ high-growth markets, along with analyzing the impact COVID-19 has had on the pharmaceuticals industry in general, and hyaluronic acid products in particular.
How Does the Historical and Future Outlook of Hyaluronic Acid Products Market Compare?
With ageing, the risk of complications such as dermal problems, arthritis, inflammatory diseases, and ophthalmic diseases increases. Therefore, the greying population has been exhibiting high demand for medication for the treatment of these indications. Hyaluronic acid products comprises a substantially essential component for the pain management therapies and moisture restorative therapy for dry eyes and others.
Countries such as Japan, Italy, Germany, and others have been exhibiting high demand on account of the increasing aging population. According to FMI’s analysis, hyaluronic acid products sales have grown at 5.5% CAGR between 2015 and 2019.
The surging demand for minimally invasive treatment is giving a push to the hyaluronic acid products sales growth. This has been encouraging some of the leading beauty brands to include hyaluronic acid as a key ingredient. For instance, the Croma-Pharma has used 1.8% of hyaluronic acid in its face masks for skin revitalization and provide skin radiance. The advanced sodium hyaluronate based intra-articular viscosupplement by Fidia Farmaceutici S.p.A., TRILURON and EUFLEXXA by Ferring Pharmaceuticals has been launched that offers minimally invasive treatment for the osteoarthritis pain.
Bausch Health Companies Inc. owns an impressive range of hyaluronic acid-based eye lubricants for dry eye diseases, including Artelac, Biotrue and others. The skin care segment also has witnessed new arrivals of hyaluronic acid-based dermal fillers, including the Restylane Kysse by Galderma, indicated for wrinkle augmentation of upper perioral rhytids correction and lips.
The aging population, rising demand of the minimally invasive therapies, and launch of advanced dermatological procedures by the key manufacturers are propelling the growth of the hyaluronic acid products market.
The pandemic has shaken several industries with complete lockdown imposed after its outbreak. The fear of infections and deaths curbed the normal treatment regime of other OPDs such as dermatology, ophthalmology and orthopaedics. As a result, the demand and supplies of hyaluronic acid products were affected, leading to a subdued growth of the market.
Nonetheless, FMI expects global hyaluronic acid products market to recover, exhibiting growth at 6.1% CAGR through 2030.
How is Demand for Minimally Invasive Therapies Influencing Hyaluronic Acid Products Sale?
The minimal invasive therapies are in high demand due to the assured minimal adverse effects of the post-operative procedures complications, minimal pain, shorter recovery time, and shorter hospital stay period. The dosage forms of the HA are majorly provided as injections and dermal filler for aesthetic applications.
The complication of vesicoureteral reflux (VUR) is more prevalent among children of ged below 5 years, which necessitates the treatment to be less painful and invasive. HA-based treatment drives the hyaluronic acid products demand growth in the section of minimally invasive procedures and therapies indicated for the complication where there is a medical-comorbidities such as diabetes.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
What is the Commercial Potential of Hyaluronic Acid in Dermal Fillers?
Dermal fillers are injectable implants which are indicated for the aesthetic skin treatments to fix aging related wrinkles. Dermal fillers provide a smooth appearance to the face, cheeks, lips, chin, nasolabial folds, and back of the hands.
Dermal fillers have seen a surge in demand in the recent decade owing to advancements in rejuvenating and aesthetic procedures. With the cost efficiency, fast recovery time and rising awareness, dermal filler applications are elevating.
The American Society for Aesthetic Plastic Surgery (ASAPS) has stated that more than 1.6 million dermal filler treatments were carried out in 2011. This makes dermal filler the second most popular nonsurgical cosmetic procedure after neuromodulators, in U.S.
The commonly used dermal fillers include Restylane Fine lines/Restylane Touch, Restylane Perlane, Captique and Juvederm Ultra (2, 3, and 4) and Juvederm Ultra XC.
What is the Impact of Emerging Alternative Therapies on Hyaluronic Acid Products Sales?
There are several emerging alternative therapies for the pain management of osteoarthritis. Several competing molecules such as corticosteroids, OTC (over-the-counter) compositions, COX-2 inhibitors and others are being utilized for various indications covered by hyaluronic acid.
The arthroscopic surgery, joint replacement and osteotomy also occupy a substantial volume in the osteoarthritis treatment. The stem cell therapy also poses a potential competition to hyaluronic acid products in the domain of osteoarthritis. The availability of these alternative therapies is likely to hamper the hyaluronic acid products sale.
For instance, Japan has a dedicated R&D for the stem therapy of osteoarthritis for its geriatric patients. The availability of these alternatives is expected to restrict growth prospects for the market.
How Big is the Opportunity in US?
In the U.S., the healthcare system is well known for its expenditure and advanced infrastructure. The care regime of care centres and hospitals are scrutinized by regulatory rules. Government and regulatory bodies of the U.S. are adopting various cost-effective plans to reduce their healthcare burden.
Furthermore, due to the higher prevalence of osteoarthritis, the demand for hyaluronic acid products is increasing. According to, A National Public Health Agenda for Osteoarthritis, 2020, osteoarthritis (OA) is the most common form of arthritis, a serious chronic disease that affects 1 in 7 US adults - 32.5 million people. OA is associated with aging and is more common among people with other chronic conditions, such as diabetes, heart disease, and obesity. In U.S., it is predicted that by 2050, over 15% of population will be affected with osteoarthritis.
How is the Hyaluronic Acid Products Market of Germany Performing?
The German healthcare system is a universal, multi-payer system that is largely funded by the government. It is one of the most successful healthcare systems in the world. It is not surprising that Germany has the highest level of spending in Europe.
Furthermore, the presence of several key players, rising geriatric, population and rising technological advancements in the country creates a huge opportunity for the hyaluronic acid products market to grow. The Germany hyaluronic acid products demand is expected to reach 2,52 Mn by the end of 2030.
Rising Geriatric Population in China to Boost Hyaluronic Acid Products Sales
Geriatric population are more prone to osteoarthritis, which might require treatment including hyaluronic acid products. Improvement in health care reforms in China has improved access to various treatment options, thereby increasing life expectancy of respective populations. According to WordBank, the Chinese geriatric population, which was pegged at 8.2% of the Chinese population Mn in 2010, has reached approximately 10% in 2016 and expected to grow in coming years.
Rise in geriatric population will intensify the need for health care products and services since this segment of the population is more prone to orthopedic diseases such as osteoporosis, arthritis etc. Early diagnosis of these diseases is crucial for decision making and ensuring proper treatment. According to The United Nations projection, over 400 million, or nearly 33%, of Chinese citizens are expected to be over 60 years old by 2050. The hyaluronic acid products demand in China is expected to witness significant growth at a CAGR of around 9.5%.
What are the Restrains that Turkey Hyaluronic Acid Products Market Might Face?
Lack of skilled professionals and the unavailability of dermal products restrain the growth of the hyaluronic acid products in the country. Furthermore, most of the scar revision treatments require multiple clinic visits during the treatment regime for osteoarthritis, dermal applications and VUR. The multiple visits incur excessive charges and hassle for the patients.
Why Three Cycle Injection Products Dominate the Hyaluronic Acid Products Market?
In terms of revenue, three cycle injection products emerged dominant in the global hyaluronic acid products market in 2019. The segment is expected to further gain traction, owing to its functional benefits for treatment of several conditions of osteoarthritis, dermal fillers and others.
Three cycle injection products segment is expected to register the fastest CAGR of 6.5% during forecast period and is expected to gain significant market share by 2030 end, owing to the increased number of usage of hyaluronic acid products.
What’s the Revenue Share of Dermal Fillers?
The dermal fillers segment will continue to grow and dominate the hyaluronic acid products market during the forecast period. According to FMI, the segment is expected to hold around 36.5% of the market share, in terms of application, by the end of 2030. The dermal fillers hold the dominance owing to the advanced dermal filler technology and high expenditure of the dermal filler products based on hyaluronic acid.
The rising popularity of the beauty aesthetic industry with the massive usage of hyaluronic acid injections, masks, and fillers are creating opportunities for market growth. The hyaluronic acid products are extensively used in the treatment regime of osteoarthritis.
Which Distribution Channel Remains More Preferred?
Hospitals will continue dominating the market through the forecast period. The higher footfall of patients besides presence of more advanced infrastructure will continue supporting growth in the segment. Moreover, hospitals offer a perfect infrastructure for conducting various procedures, including minimally invasive or non-invasive treatment under the presence of experts. This will seal hospitals’ dominance in the global market.
The hyaluronic acid products market comprises of both big as well as small regional players. These companies are focusing on expanding their portfolio to gain competitive strength. Besides this, focus on merger and acquisitions continue to remain high.
For instance, Bausch Health Companies Inc. acquired Salix pharmaceuticals on 01 April 2015, the acquisition has robustly elevated the hyaluronic acid-based products for ophthalmic applications.
Galderma of Nestlé, on 03 January 2017, launched a next-generation hyaluronic acid (HA) dermal fillers, Restylane Refyne and Restylane Defyne, which are indicated for the facial wrinkles and folds.
These dynamic strategies adopted by key players will have significant impact on the market.
Some of the leading companies operating in the hyaluronic acid products market are:
- Anika Therapeutics, Inc.
- Fidia Farmaceutici S.p.A.
- Ferring B.V.
- Viatris Inc.
- Seikagaku Corporation
- Zimmer Biomet
- Lifecore Biomedical, LLC
- LG Chem
- Bioventus LLC
- Smith & Nephew plc
- Shanghai Jingfeng Pharmaceutical Co., Ltd.
- Nestle (Galderma)
- Bausch Health Companies Inc. Companies Inc. (Salix Pharmaceuticals, Inc.)
- Allergan Plc.
*The list is not exhaustive, and only for representational purposes. Full competitive intelligence with SWOT analysis available in the report.
Scope of the Report
Historical Data Available for
USD Million for Value and Units for Volume
Key Regions Covered
North America, Latin America, Europe, East Asia, South Asia, Oceania Middle East & Africa
Key Countries Covered
US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa
Key Segments Covered
Product, Application, Distribution Channel, and Region
Key Companies Profiled
Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing
Key Questions Answered in the Report
Which is the most lucrative market for hyaluronic acid products?
The U.S. currently leads the global market for hyaluronic acid products. Sales in the U.S. will account for over 22% of total global demand throughout the forecast period.
Which is the top-selling hyaluronic acid product?
Dermal fillers are dominating the hyaluronic acid products segment as compared to other products. The rising demand for various aesthetic procedures to prevent skin aging will aid expansion in the segment.
Which are some of the leading companies offering hyaluronic acid products?
Some of the leading companies offering hyaluronic acid products are Anika Therapeutics, Inc. Fidia Farmaceutici S.p.A., Sanofi, Ferring B.V., Viatris Inc., Croma-Pharma, Seikagaku Corporation, Zimmer Biomet, Lifecore Biomedical, LLC, LG Chem, Bioventus LLC, Smith & Nephew plc, Shanghai Jingfeng Pharmaceutical Co., Ltd., Nestle (Galderma), Bausch Health Companies Inc. Companies Inc. (Salix Pharmaceuticals, Inc., Allergan Plc., and others.
Which distribution channel is driving maximum revenue for hyaluronic acid products?
Hospital pharmacies is leading the distribution channel segment of the hyaluronic acid products market.
Enquiry before Buying
Is this research conducted by Future Market Insights?
Yes, the research has been conducted by expert analysts of Future Market Insights through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to research analyst
What research methodology is followed by FMI?
FMI follows a methodology that encompasses demand side assessment of the market, and triangulates the same through supply side analysis. This methodology is based on use of standard market structure, methods and definitions. Request detailed methodology
Who are the respondents for primary research?
FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. For a full list of primary respondents, please reach out to us.
What are the sources of secondary research?
FMI conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Is a sample of this report available for evaluation?
Yes, you can request a sample and it will be sent to you through an email.
How can I buy this report?
FMI provides a secure online payment system to buy report seamlessly. You can buy the report securely and safely.
Hyaluronic Acid Products Market by Category
- Single Cycle Injection Products
- Three Cycle Injection Products
- Five Cycle Injection Products
- Dermal Fillers
- Vesicoureteral Reflux
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Speciality Clinics
- North America
- Latin America
- East Asia
- South Asia
- Middle East and Africa (MEA)